Cash pulled forward: buyers are funding the company's next stage in advance, and the money keeps arriving
The model's full reasoning — Q2 2022 call → NOWe need to determine if management describes advance funding from counterparties that is growing and financing the company's next stage. The transcript discusses various partnerships, but does it mention customers paying upfront, deposits, prepayments, or binding commitments that oblige them to pay before delivery? The eXtend model with Pilot/GM: EVgo procures, constructs, operates, maintains chargers, but the customer (Pilot/GM) incurs upfront capital expenditures. EVgo generates margin as developer/builder and ongoing service revenues. That means the counterparty is funding the capital, but EVgo is not receiving cash in advance; rather, EVgo is providing services and getting paid over time. The customer pays for the construction? Actually, EVgo builds and the customer pays? The description: "our customer incurs the upfront capital expenditures, while EVgo generate margin as the developer and builder of the project, as well as going forward as we earn ongoing revenues from providing operations, maintenance and networking and software integration services under the contract." So EVgo is not receiving advance cash; the customer is paying for the capital, but EVgo is being paid for its services as it performs them. That's not advance funding to EVgo. Also, there's no mention of deposits, prepayments, or growing advance balances. The LCFS credits are sold, but that's normal revenue. No mention of customers paying before delivery. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
SYM · Q3 2022 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes a "very significant cost float" from "strong deferred revenue on the balance sheet" that helps fund the company's growth strategy, along with improved payable terms. This ties directly to the $11.3 billion backlog and the ability to invest aggressively in scaling deployments, inventory, and operations ahead of full revenue recognition.
IONS · Q1 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes exactly this pattern: Novartis delivered $175 million (including $75 million upfront plus $100 million equity at a premium) before the Phase IIb studies are conducted, and Bayer paid $75 million to advance IONIS-FXIRx and IONIS-FXI-LRx before full development work is complete 65-plus percent of which was already recognized in Q1.
LIND · Q2 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and if they treat this as growing and financ...YES The transcript shows management describing a clear pattern of advance bookings and forward reservations that are growing (nearly 40% year-to-date, up nearly 50% in July, highest booking day ever) and that directly de-risk and finance the next stage of growth.